Stock Events

Stock Events

Insulet

$167.53

122

-$3.86-2.25% Tuesday 20:00

Statistics

Day High

170.98

Day Low

166.74

52W High

352.82

52W Low

160.02

Volume

1,455,914

Avg. Volume

-

Mkt Cap

11.79B

P/E Ratio

50.3

Dividend Yield

-

Dividend

-

Upcoming

Earnings

6MayExpected

Q3 2024

Q4 2024

Q1 2025

Q2 2025

Q3 2025

Q4 2025

Next

0.78

1.04

1.29

1.55

Expected EPS

1.198712

Actual EPS

N/A

Financials

9.12%Profit Margin

Profitable

2020

2021

2022

2023

2024

2025

5.42BRevenue

494.2MNet Income

Analyst Ratings

330.69Average Price Target

The highest estimate is 435.00.
From 16 ratings within the last 6 months. This is not an investment recommendation.

Buy

81%

Hold

13%

Sell

6%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PODD. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Tandem Diabetes Care

Tandem Diabetes Care, Inc. competes directly with Insulet by offering insulin pump therapy for diabetes management, which is a direct alternative to Insulet's Omnipod system.

Medtronic plc is a major competitor in the insulin pump market, offering a range of products that compete with Insulet's offerings for diabetes management.

DexCom, Inc. provides continuous glucose monitoring (CGM) systems that are often used in conjunction with insulin pumps like those offered by Insulet, making them a competitor in the broader diabetes management space.

Abbott Laboratories

Abbott Laboratories offers the FreeStyle Libre, a CGM system that competes with the integrated diabetes management solutions provided by Insulet.

Insulet Corporation is listed as its own competitor due to an error. Please disregard this entry.

Senseonics Holdings, Inc. offers the Eversense CGM system, which competes in the diabetes management market by providing an alternative to the CGM solutions that can be used with Insulet's products.

Novo Nordisk A/S is a leading provider of insulin and other diabetes care products that, while not a direct competitor in the insulin pump market, competes in the broader diabetes management space.

Sanofi provides a range of diabetes care solutions, including insulin therapies that compete with the insulin management solutions offered by Insulet.

MannKind Corporation offers Afrezza, an inhaled insulin, providing a non-injectable alternative to insulin delivery that competes with traditional pump therapies like those offered by Insulet.

About

There is no Profile data available for GOV.MU.

Show more...

CEO

Ms. Ashley A. McEvoy

Employees

5400

Country

United States

ISIN

US45784P1012

Listings

0 Comments

Share your thoughts

FAQ

What is Insulet stock price today?▼

The current price of PODD is $167.53 USD — it has decreased by -2.25% in the past 24 hours. Watch Insulet stock price performance more closely on the chart.

What is Insulet stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Insulet stocks are traded under the ticker PODD.

Is Insulet stock price growing?▼

PODD stock has risen by +4.69% compared to the previous week, the month change is a -17.68% fall, over the last year Insulet has showed a -35.28% decrease.

What is Insulet market cap?▼

Today Insulet has the market capitalization of 11.79B

What is Insulet revenue for the last year?▼

Insulet revenue for the last year amounts to 5.42B USD.

What is Insulet net income for the last year?▼

PODD net income for the last year is 494.2M USD.

How many employees does Insulet have?▼

As of May 06, 2026, the company has 5,400 employees.

In which sector is Insulet located?▼

Insulet operates in the Health & Wellness sector.

When did Insulet complete a stock split?▼

Insulet has not had any recent stock splits.

Where is Insulet headquartered?▼

Insulet is headquartered in Acton, United States.